**Amendment 339**
*Catherine Soullie, Françoise Grossetête, Amalia Sartori and others*

**Report**
*Christa Klaß*
Placing on the market and use of biocidal products

**Proposal for a regulation**
**Article 9 – paragraph 1 – point c**

<table>
<thead>
<tr>
<th>Text proposed by the Commission</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>(c) there are reasons for concern linked to the nature of the critical effects, in particular developmental neurotoxic or immunotoxic effects, which, in combination with the use patterns, amount to use that could still cause concern, even with very restrictive risk management measures;</td>
<td>(c) it is very persistent and very bioaccumulative in accordance with the criteria set out in Annex XIII of Regulation (EC) No 1907/2006;</td>
</tr>
</tbody>
</table>

Or. en
Amendment 340
Catherine Soullie, Françoise Grossetête, Amalia Sartori and others

Report
Christa Klaß
Placing on the market and use of biocidal products

Proposal for a regulation
Article 9 – paragraph 1 – point f

Text proposed by the Commission
(f) it is considered to have endocrine disrupting properties that may cause adverse effect on humans on the basis of the assessment of Community or internationally agreed test guidelines or other available data.

Amendment
(f) there is scientific evidence of the substance (such as one having endocrine disrupting properties or persistent, bioaccumulative and toxic properties or very persistent and very bioaccumulative properties, which does not fulfil the criteria set out in points (b) or (c)) having probable serious effects to human health or the environment which give rise to an equivalent level of concern to those of other substances that fulfil the criteria listed in points (b), (c) or (e) and which are identified on a case-by-case basis in accordance with the procedure set out in Article 59 of Regulation (EC) No 1907/2006.